Champions Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Champions Oncology
CSBR Stock  USD 6.52  0.32  4.68%   
Champions Oncology's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Champions Oncology's valuation are provided below:
Gross Profit
28.6 M
Profit Margin
0.0826
Market Capitalization
89.8 M
Enterprise Value Revenue
1.5128
Revenue
56.9 M
There are over one hundred nineteen available fundamental signals for Champions Oncology, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to validate Champions Oncology's prevailing fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 08/17/2025, Market Cap is likely to grow to about 102.6 M. Also, Enterprise Value is likely to grow to about 98.7 M

Champions Oncology Total Revenue

59.79 Million

Check Champions Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Champions Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 38.3 K or Selling General Administrative of 9.8 M, as well as many indicators such as Price To Sales Ratio of 1.43, Dividend Yield of 0.0033 or PTB Ratio of 27.19. Champions financial statements analysis is a perfect complement when working with Champions Oncology Valuation or Volatility modules.
  
Build AI portfolio with Champions Stock
Check out the analysis of Champions Oncology Correlation against competitors.
To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide.

Champions Oncology Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets34 M32.3 M17.7 M
Slightly volatile
Short and Long Term Debt Total6.4 M6.1 M3.2 M
Slightly volatile
Other Current Liabilities2.8 M2.7 M1.3 M
Slightly volatile
Total Current Liabilities25 M23.9 M11 M
Slightly volatile
Property Plant And Equipment Net9.9 M9.5 M5.7 M
Slightly volatile
Accounts Payable4.5 M4.2 M2.6 M
Slightly volatile
Cash10.3 M9.8 M5.9 M
Slightly volatile
Non Current Assets Total10.5 M10 M6.3 M
Slightly volatile
Non Currrent Assets Other223.4 K212.8 K142.2 K
Very volatile
Cash And Short Term Investments10.3 M9.8 M5.9 M
Slightly volatile
Net Receivables11.8 M11.2 M4.8 M
Slightly volatile
Common Stock Total Equity24.7 K16.1 K26.1 K
Slightly volatile
Common Stock Shares Outstanding15 M14.3 M10.2 M
Slightly volatile
Liabilities And Stockholders Equity34 M32.3 M17.7 M
Slightly volatile
Non Current Liabilities Total2.9 M4.7 M3.6 M
Slightly volatile
Other Current Assets689.9 K1.4 M817.8 K
Slightly volatile
Other Stockholder Equity87.8 M83.7 M63.8 M
Slightly volatile
Total Liabilities30 M28.6 M14.7 M
Slightly volatile
Property Plant And Equipment Gross22.2 M21.1 M7.9 M
Slightly volatile
Total Current Assets23.5 M22.4 M11.4 M
Slightly volatile
Common Stock24.4 K16.1 K26 K
Slightly volatile
Other Liabilities500.9 K633.6 K550.7 K
Pretty Stable
Other Assets16.4 K17.2 K94.5 K
Slightly volatile
Short Term Debt1.5 M1.5 M671.6 K
Slightly volatile
Property Plant Equipment17.5 M16.7 M6.8 M
Slightly volatile
Current Deferred Revenue16.2 M15.4 M6.4 M
Slightly volatile
Intangible Assets610.1 K769.4 K641 K
Slightly volatile
Good Will445.8 K301.5 K527.3 K
Slightly volatile
Capital Surpluse77.6 M94.3 M68.1 M
Slightly volatile
Non Current Liabilities Other80.8 K85 K1.3 M
Slightly volatile
Short and Long Term Debt42 K37.8 K50.9 K
Slightly volatile
Long Term Debt Total12.8 K14.4 K15.7 K
Slightly volatile
Capital Lease Obligations7.1 M6.1 M3.3 M
Slightly volatile
Capital Stock14.8 K16.1 K12.9 K
Slightly volatile

Champions Oncology Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.3 M2.1 M1 M
Slightly volatile
Selling General Administrative9.8 M9.3 M6.5 M
Slightly volatile
Total Revenue59.8 M56.9 M28.4 M
Slightly volatile
Other Operating Expenses55 M52.4 M31.9 M
Slightly volatile
Cost Of Revenue29.8 M28.4 M15.5 M
Slightly volatile
Total Operating Expenses25.2 M24 M16.5 M
Slightly volatile
Selling And Marketing Expenses4.5 M7.5 M4.3 M
Slightly volatile
Research Development5.4 M6.8 M5.3 M
Slightly volatile
Interest Income316 K355.5 K387.6 K
Slightly volatile
Reconciled Depreciation1.3 M1.6 M801.1 K
Slightly volatile
Non Recurring268 K301.5 K328.7 K
Slightly volatile

Champions Oncology Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow3.5 M2.6 M5.5 M
Very volatile
Depreciation1.7 M1.6 M825.4 K
Slightly volatile
End Period Cash Flow10.3 M9.8 M5.9 M
Slightly volatile
Stock Based Compensation1.3 M654 K1.6 M
Slightly volatile
Change To Netincome1.6 M1.7 M2.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.431.512.8779
Slightly volatile
Dividend Yield0.00330.00370.0041
Slightly volatile
Days Sales Outstanding65.5162.3950.2507
Slightly volatile
Average Payables61.6 K47.7 K43.3 K
Slightly volatile
Stock Based Compensation To Revenue0.02440.02560.1313
Slightly volatile
Capex To Depreciation0.230.23721.7258
Pretty Stable
EV To Sales1.541.622.6437
Slightly volatile
Inventory Turnover33.8834.5129.9799
Slightly volatile
Days Of Inventory On Hand16.3213.9912.8536
Very volatile
Payables Turnover10.566.68297.0579
Very volatile
Sales General And Administrative To Revenue0.420.250.3565
Slightly volatile
Average Inventory10.1 K10.6 K10.2 K
Slightly volatile
Research And Ddevelopement To Revenue0.320.220.2544
Pretty Stable
Capex To Revenue0.02220.0150.037
Pretty Stable
Cash Per Share0.620.71630.7384
Slightly volatile
Days Payables Outstanding57.1254.616964.9513
Pretty Stable
Intangibles To Total Assets0.00980.01040.1054
Slightly volatile
Current Ratio1.50.93781.3433
Slightly volatile
Receivables Turnover5.756.058.3215
Slightly volatile
Graham Number1.51.680.6833
Slightly volatile
Capex Per Share0.05390.02850.0931
Slightly volatile
Average Receivables12.4 K13.1 K14.4 K
Slightly volatile
Revenue Per Share2.724.262.6297
Slightly volatile
Interest Debt Per Share0.470.44690.2505
Slightly volatile
Debt To Assets0.20.18880.1173
Slightly volatile
Operating Cycle65.5162.3951.3268
Slightly volatile
Days Of Payables Outstanding57.1254.616964.9513
Pretty Stable
Ebt Per Ebit1.661.0161.3432
Slightly volatile
Total Debt To Capitalization0.420.61810.5332
Slightly volatile
Quick Ratio1.460.93781.3288
Slightly volatile
Net Income Per E B T1.41.01621.1929
Slightly volatile
Cash Ratio0.390.41020.8487
Slightly volatile
Days Of Inventory Outstanding16.3213.9912.8536
Very volatile
Days Of Sales Outstanding65.5162.3950.2507
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.260.94731.0884
Very volatile
Fixed Asset Turnover4.584.8210.1576
Slightly volatile
Debt Ratio0.20.18880.1173
Slightly volatile
Price Sales Ratio1.431.512.8779
Slightly volatile
Asset Turnover2.222.211.7363
Pretty Stable
Gross Profit Margin0.530.480.4165
Slightly volatile

Champions Oncology Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap102.6 M97.7 M68.9 M
Slightly volatile
Enterprise Value98.7 M94 M66.5 M
Slightly volatile

Champions Fundamental Market Drivers

Forward Price Earnings22.8833
Cash And Short Term Investments9.8 M

Champions Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
22nd of July 2024
Next Financial Report
View
31st of January 2024
Next Fiscal Quarter End
View
22nd of July 2024
Next Fiscal Year End
View
31st of October 2023
Last Quarter Report
View
30th of April 2023
Last Financial Announcement
View

About Champions Oncology Financial Statements

Champions Oncology shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Champions Oncology investors may analyze each financial statement separately, they are all interrelated. The changes in Champions Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Champions Oncology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue15.4 M16.2 M
Total Revenue56.9 M59.8 M
Cost Of Revenue28.4 M29.8 M
Stock Based Compensation To Revenue 0.03  0.02 
Sales General And Administrative To Revenue 0.25  0.42 
Research And Ddevelopement To Revenue 0.22  0.32 
Capex To Revenue 0.02  0.02 
Revenue Per Share 4.26  2.72 
Ebit Per Revenue(0.17)(0.18)

Pair Trading with Champions Oncology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.

Moving against Champions Stock

  0.5DRUG Bright Minds BiosciencesPairCorr
  0.35VALN Valneva SE ADRPairCorr
  0.35DTIL Precision BioSciencesPairCorr
  0.34DMAC DiaMedica TherapeuticsPairCorr
  0.33DRMA Dermata TherapeuticsPairCorr
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Champions Stock Analysis

When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY